Results 271 to 280 of about 36,696 (303)
Some of the next articles are maybe not open access.
Sulfonylureas have been a mainstay in the pharmacologic treatment of T2D for over 60 years. The first-generation sulfonylureas (e.g., chlorpropamide, tolbutamide, and tolazamide) are no longer available in the United States. With the availability of many noninsulin classes of medications for T2D, sulfonylurea usage is on the decline, yet their use ...
Elmo M. Beyer +3 more
openaire +2 more sources
Elmo M. Beyer +3 more
openaire +2 more sources
Sulfonylurea Signal Transduction
1991In the pancreatic beta cells the proximal step in sulfonylurea signal transduction is the binding of these clinically important drugs to high-affinity receptors in the beta cell membrane. Using HIT cells as a model system, we have established an extremely close correlation between the affinity of binding of glyburide and its analog, iodoglyburide, and ...
A E, Boyd +9 more
openaire +2 more sources
Hyperlipemia and Sulfonylurea Therapy
JAMA, 1964To the Editor:— A report by Shipp et al ( JAMA 188: 468 [May 4] 1964), describing severe hyperlipemia in three diabetics treated with sulfonylurea compounds, proposes that "... enough control to prevent ketosis, but not enough to prevent hyperglycemia, may have provided a longterm metabolic balance favoring the development of hyperlipemia." It is ...
openaire +2 more sources
Management of sulfonylurea ingestions
Pediatric Emergency Care, 1999In the majority of pediatric patients with an unintentional ingestion of a sulfonylurea, observation and, if necessary, intravenous glucose supplementation, are sufficient. However, with cases of persistent hypoglycemia or cases refractory to IV glucose supplementation, attempts to inhibit insulin secretion should be considered.
openaire +2 more sources
Postgraduate Medicine, 1992
The clinical use of sulfonylureas described in this article is both rational and effective for diabetic patients. Sulfonylureas are not used (1) in patients with insulin-dependent (type I) diabetes, because they are completely ineffective or (2) in patients with non-insulin-dependent (type II) diabetes who respond satisfactorily to diet, because they ...
openaire +2 more sources
The clinical use of sulfonylureas described in this article is both rational and effective for diabetic patients. Sulfonylureas are not used (1) in patients with insulin-dependent (type I) diabetes, because they are completely ineffective or (2) in patients with non-insulin-dependent (type II) diabetes who respond satisfactorily to diet, because they ...
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2015
SU drug promotes insulin secretion by acting on pancreatic β cell. The hypoglycemic effect is the most powerful among oral diabetic drugs with high cost-effectiveness. Particularly for the Japanese with type 2 diabetes caused by a decrease in insulin secretion as a main pathological condition, it was widely used until the present since 1957 and largely
openaire +1 more source
SU drug promotes insulin secretion by acting on pancreatic β cell. The hypoglycemic effect is the most powerful among oral diabetic drugs with high cost-effectiveness. Particularly for the Japanese with type 2 diabetes caused by a decrease in insulin secretion as a main pathological condition, it was widely used until the present since 1957 and largely
openaire +1 more source
Clinical pharmacology of sulfonylureas
Metabolism, 1987Sulfonylureas seem to have similar mechanisms of action, including an acceleration and increase of insulin secretion, an increase of the systemic availability of insulin, and probably indirectly, an increase of insulin action. Sulfonylureas may postpone the development of impaired glucose tolerance (IGT) to manifest non-insulin-dependent diabetes ...
openaire +2 more sources